Market cap
$2 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
7.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 0.00 | 104.81 | 472.58 | -7.60 | 10.60 |
| EBIT | -- | 12.85 | 6.98 | 8.00 | 8.57 |
| Net Profit | 0.00 | 13.42 | 5.60 | 3.61 | -177.23 |
| EPS | -27.52 | 45.25 | 81.07 | 24.62 | 14.65 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-25 | Dec-24 | Dec-23 |
| EBIT-Margin
| -2,278.45 | -5,809.02 | -249.74 | -3,100.17 | -3,485.44 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -174.80 | -120.75 | 104.38 | 776.58 | -1,405.34 |
| Return on Capital
| -21.86 | 21.95 | 231.87 | 823.24 | -1,120.70 |
| Return on Assets
| -395.59 | -323.17 | -239.36 | -598.49 | -348.91 |
| Debt to Equity (x)
| -- | -- | -0.73 | -0.01 | -0.11 |
Profitability
ROCE
231.87
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
231.87
|
823.24
|
-1,120.70
|
-292.61
|
467.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
104.38
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
104.38
|
776.58
|
-1,405.34
|
-312.92
|
233.58
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-239.36
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
-239.36
|
-598.49
|
-348.91
|
-221.35
|
-207.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-249.74
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
-249.74
|
-3,100.17
|
-3,485.44
|
-19,813.00
|
-2,396.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-251.07
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
-251.07
|
-3,100.50
|
-3,552.81
|
-19,722.00
|
-2,486.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
2.49
--
Year on year growth in net sales
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
2.49
|
0.05
|
4.70
|
-0.89
|
17.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
71.92
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
71.92
|
6.22
|
-0.27
|
8.15
|
23.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
71.77
--
Year on year growth in profit after tax
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
71.77
|
7.98
|
-2.68
|
11.88
|
22.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.64
--
Year on year growth in earnings per share
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
0.64
|
0.69
|
0.77
|
0.36
|
0.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.73
--
Total debt / Net worth
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
-0.73
|
-0.01
|
-0.11
|
0.09
|
0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
--
|
-0.01
|
-0.10
|
0.05
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.45
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
0.45
|
0.50
|
0.57
|
2.95
|
4.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
--
|
--
|
--
|
2.95
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-39.64
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
-39.64
|
-9,316.00
|
-19,867.00
|
-9,906.50
|
-26.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
55.13
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
55.13
|
139.43
|
168.60
|
175.00
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.95
--
Sales / Average Total Assets
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
0.95
|
0.19
|
0.10
|
0.01
|
0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
173.73
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
173.73
|
546.66
|
363.97
|
319.59
|
31.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
--
|
--
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
38,732.15
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
38,732.15
|
--
|
5,458.80
|
2,275.31
|
4,571.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
--
|
--
|
-5,094.83
|
-1,955.72
|
-4,539.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
--
|
-0.14
|
-0.03
|
-0.01
|
-0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
--
|
-1.05
|
-0.25
|
0.03
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
--
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
--
|
-0.08
|
0.04
|
0.29
|
0.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|